Biomarker analysis for patients with pancreatic cancer treated with nanoliposomal irinotecan plus 5-fluorouracil/leucovorin

Biomarker analysis for patients with pancreatic cancer treated with nanoliposomal irinotecan plus 5-fluorouracil/leucovorin

Abstract Background Nanoliposomal irinotecan plus fluorouracil/leucovorin (5-FU/LV) is a standard second-line therapy for patients with pancreatic cancer. Identification of biomarkers is important to determine appropriate treatment strategies. We investigated the clinical practice outcomes and bioma...

Full description

Bibliographic Details
Main Authors: Takeshi Kawakami, Akiko Todaka, Kotoe Oshima, Kunihiro Fushiki, Satoshi Hamauchi, Takahiro Tsushima, Tomoya Yokota, Yusuke Onozawa, Hirofumi Yasui, Kentaro Yamazaki
Format: Article
Language:English
Published: BMC 2023-01-01
Series:BMC Cancer
Subjects:
Pancreatic cancer
Nanoliposomal irinotecan
GPS
NLR
Biomarker
Online Access:https://doi.org/10.1186/s12885-023-10542-w

Similar Items

Similar Items